School of Bioengineering, SRM University, Kattankulathur, Tamil Nadu, 603203, India.
Charles Darwin University, Ellengowan Dr, Casuarina, NT, 0810, Australia.
Syst Rev. 2018 Oct 2;7(1):150. doi: 10.1186/s13643-018-0812-8.
Head and neck cancers form a significant share of all cancer incidences worldwide. Though treatment modalities exist, post-treatment recurrence and survival rates in recurrent patients continue to be high. MiRNAs offer an effective method of estimating the probability of recurrence and survival of HNC patients, thereby allowing for effective treatment and better survival rates.
The systematic review protocol was prepared according to the Preferred Reporting Items for Systematic Review and Meta-Analyses Protocols (PRISMA-P) 2015 statement. Relevant studies will be identified by a rigorous search of multiple bibliographical databases, including MEDLINE, Scopus, PubMed, Web of Science, Embase and Science Direct, without any language restrictions (up to June 2018). The primary screening will be performed by a review team via analysis of titles and abstracts of published articles. Final selection of articles will be achieved by two independent reviewers, based on predefined selection criteria. Data will be extracted from eligible studies using a pre-piloted data extraction form. Statistical analysis will be performed on the basis of available data, extracted from eligible studies. Meta-analysis will be performed, and a forest plot will be generated, to determine pooled hazard ratios (HR) and 95% confidence interval (CI) using CMA. A fixed or random-effects model of meta-analysis will be used depending upon the between-study heterogeneity; publication bias will be determined by the Egger's bias indicator test. A narrative synthesis will be undertaken where statistical data is found to be insufficient.
There is a lack of highly sensitive and specific biomarkers for estimating the HNC patients' prognostic outcomes, particularly in post-treatment conditions. This systematic review will identify and validate specific miRNA as prognostic biomarkers by utilising a collection of previously published data on miRNA expression and survival. Highlighting these prognostic specific miRNAs will have major clinical implications by allowing for better overall treatment strategies and patient survival estimates, by offering clinicians a method of quantitatively analysing prognosis via miRNA expression.
This review protocol was registered on PROSPERO and assigned the registration number CRD42017077411 .
头颈部癌症在全球所有癌症发病率中占很大比例。尽管存在治疗方法，但复发患者的治疗后复发和生存率仍然很高。miRNA 提供了一种有效估计头颈部癌症患者复发和生存概率的方法，从而可以进行有效治疗并提高生存率。
根据 2015 年系统评价和荟萃分析报告的首选报告项目（PRISMA-P）声明，制定了系统评价方案。将通过严格搜索多个文献数据库（包括 MEDLINE、Scopus、PubMed、Web of Science、Embase 和 Science Direct）来识别相关研究，不限制任何语言（截至 2018 年 6 月）。通过分析已发表文章的标题和摘要，由一个审查团队进行初步筛选。根据预先确定的选择标准，由两名独立评审员对文章进行最终选择。将使用预制定的数据提取表从合格研究中提取数据。将根据可从合格研究中提取的数据进行统计分析。将使用 CMA 进行荟萃分析，并生成森林图，以确定合并风险比（HR）和 95％置信区间（CI）。将根据研究之间的异质性使用固定或随机效应模型进行荟萃分析；将通过 Egger 偏倚指标检验确定发表偏倚。如果发现统计数据不足，将进行叙述性综合。
目前缺乏用于评估头颈部癌症患者预后结果的高度敏感和特异的生物标志物，特别是在治疗后情况下。本系统评价将通过利用以前发表的 miRNA 表达和生存数据，确定并验证特定的 miRNA 作为预后生物标志物。通过允许更好的总体治疗策略和患者生存估计，为临床医生提供通过 miRNA 表达定量分析预后的方法，突出这些预后特异性 miRNA 将具有重要的临床意义。
本研究方案已在 PROSPERO 上注册，并分配了注册号 CRD42017077411。
